Opthea

Opthea Earnings CAGR 5Y

Delisted·Sep 9, 2026

The Earnings CAGR (5 Year) of Opthea (OPT.AX) as of Nov 19, 2026 is 71.03 %. In the previous year, Earnings CAGR (5 Year) was 71.03 % — a change of 0.00% (lower).

Earnings CAGR 5Y

71.03 %

YoY

0.00%

Last updated:

Earnings CAGR (5 Year) of Opthea is 2025 71.03 % . Earnings CAGR (5 Year) of Opthea was 2024 71.03 % . It decreases by 0.00% lower compared to the previous year.

The Opthea Earnings CAGR 5Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings CAGR 5Y
Date
Earnings CAGR 5Y
Jan 1, 2018
71.03 USD
Jan 1, 2019
71.03 USD
Jan 1, 2020
71.03 USD
Jan 1, 2021
71.03 USD
Jan 1, 2022
71.03 USD
Jan 1, 2023
71.03 USD
Jan 1, 2024
71.03 USD
Jan 1, 2025
71.03 USD
The Opthea Earnings CAGR 5Y history
YEAREarnings CAGR 5YYoY
71.03 %0.00%
71.03 %0.00%
71.03 %0.00%
71.03 %0.00%
71.03 %0.00%
71.03 %0.00%
71.03 %0.00%
71.03 %0.00%
71.03 %0.00%
71.03 %0.00%
71.03 %0.00%
71.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Opthea Stock analysis

What does Opthea do? Opthea Ltd is a biopharmaceutical company specializing in the development of novel therapies for various eye diseases. The company was founded in 1985 in Melbourne, Australia as a spin-off from the Burnet Institute for Medical Research and Public Health. Since then, Opthea has become a leading company in ophthalmology and is researching innovative therapies that have the potential to improve the lives of millions of patients worldwide. Opthea's business model is to develop novel therapies for various eye diseases and market these therapies through partnerships with established pharmaceutical companies. The company focuses on developing therapies based on the inhibition of growth factors and other signaling pathways that promote the development of abnormal blood vessels and inflammation. This therapeutic principle offers a promising way to effectively treat various eye diseases. Opthea specializes in developing therapies for the treatment of wet age-related macular degeneration (AMD), which is the leading cause of severe visual impairment in older people. Opthea is developing a therapy aimed at inhibiting the excessive formation of blood vessels in the macula of the eye, which can impair vision. The drug called OPT-302 is used in combination therapies with existing treatments for wet AMD and has the potential to slow down the progression of the disease and improve vision. In addition to the therapy for wet AMD, Opthea is also researching therapy options for other eye diseases such as diabetic retinopathy, retinal vein occlusion, and corneal diseases. Opthea has filed numerous patents in this field and collaborates with various academic and clinical partners to advance the development of innovative therapies. Another important component of Opthea's business model is collaboration with established pharmaceutical companies. In 2020, Opthea entered into a licensing agreement with the pharmaceutical company Novartis, which includes exclusive distribution and marketing rights for the drug OPT-302 in Europe, Japan, and other countries outside of North America. This partnership allows Opthea to benefit from collaboration with an experienced and established partner while maximizing the potential of its innovative therapy. In summary, Opthea is a promising company in ophthalmology that specializes in the development of innovative therapies for various eye diseases. The company works closely with academic and clinical partners and leverages the advantages of partnerships with established pharmaceutical companies to maximize the potential of its therapies. With the therapy for wet AMD already in the pipeline, Opthea is expected to develop further therapy options in the future that will contribute to improving the lives of millions of patients worldwide. Opthea is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Opthea stock

Earnings CAGR (5 Year) of Opthea is 71.03 % in 2025.

On Eulerpool you can find the complete historical development of Earnings CAGR (5 Year) Opthea since 2006 – with annual values, charts, and detailed analysis.

The 5-year earnings CAGR shows the compound annual growth rate of net income over five years, indicating medium-term profitability trends.

To evaluate Earnings CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings CAGR (5 Year).

Earnings CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Earnings CAGR (5 Year)'s Opthea historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Opthea

All Key Metrics — Opthea